Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Inhaled Ad5 and ChAd Trivalent COVID-19 Vaccines
NCT05094609Phase 1Completed
- Sponsor
- McMaster University
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5-triCoV/Mac and ChAd-triCoV/Mac in coronavirus disease 2019 (COVID-19) (10 arms), sponsored by McMaster University. Primary endpoint: Number of participants reporting adverse events and severity of adverse events at 48 weeks. Started Jan 2022; status: completed.
02
Drugs
Ad5-triCoV/MacChAd-triCoV/Mac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05094609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094609.